Vertex Pharmaceuticals (VRTX) Short-Term Debt issuances (2017)

Vertex Pharmaceuticals' (VRTX) quarterly Short-Term Debt issuances came in at $300.0 million in Q1 2017.

Vertex Pharmaceuticals (VRTX) Short-Term Debt issuances (2017) Analysis & Trends

Vertex Pharmaceuticals' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at $300.0 million for Q1 2017.

On a quarterly basis, Short-Term Debt issuances changed N/A year-over-year to $300.0 million in Q1 2017; TTM through Dec 2017 was $300.0 million, a N/A change from a year earlier, with the FY2017 full-year figure at $300.0 million, changed N/A from the prior year.
Short-Term Debt issuances held at $300.0 million in Q1 2017 per VRTX's latest filing.
Across five years, Short-Term Debt issuances topped out at $300.0 million in Q1 2017 and bottomed at $300.0 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	58.20 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Alnylam Pharmaceuticals	35.71 Bn	32.70 Bn	959.66 Mn	-

Download Data

Date	Value
Mar 31, 2017	300.00 Mn
Mar 31, 2017	300.00 Mn